We want to hear from you: what is the limiting factor in managing adverse events in patients with cancer?
The American Society of Pharmacovigilance officially announced that today, March 24, is National Adverse Drug Event Awareness Day. In the oncology world, nurses are leaders in adverse event (AE) management.
While nurses are skilled in helping patients through a variety of symptoms – from nausea to neuropathy – communication barriers may exist between patients and providers, leading to unchecked toxicities that diminish patient health and quality-of-life. For example, research shows that patients receiving immunotherapy may not report AEs, in fear of being taken off treatment. In this situation, reassurance from the nurse is critical.1
Patients may also be unaware of what kind of AEs are important to look out for and report to their care team, or may not have a solid understanding of their cancer treatment plan.This points toward the importance of patient education.2
We want to hear from you on the biggest barriers to AE management in patients with cancer.
What is the biggest/most frequent barrier when it comes to adverse event management?
Read more on adverse event management.
References
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”